Article info
Oral Sessions
01. Cervical cancer
342 Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study
Citation
342 Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical study
Publication history
- First published March 10, 2024.
Online issue publication
March 13, 2024
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.